Abstract
<title>Abstract</title> <p> <bold>Background</bold> : The totally implantable venous access port (TIVAP) represents a significant advancement in the field of long-term venous access, and is widely utilised in the treatment of oncology patients requiring repeated intravenous therapy. The most common implantation routes currently in use are the internal jugular vein (IJV) and the subclavian vein (SCV). The aim of this trial is to systematically evaluate the efficacy, safety and clinical outcomes of ultrasound-guided TIVAP implantation via brachiocephalic vein (BCV). <bold>Design</bold> : This prospective, multicentre, randomised controlled trial enrolled 640 eligible adult patients (aged over 18 years) and assigned them to either the control group (TIVAP implantation via IJV) or the experimental group (TIVAP implantation via BCV). The primary endpoints will be the first-attempt and technical success rates. Secondary endpoints included operative time, number of attempts, catheter length, incidence of perioperative and postoperative complications, overall complications rate, comfort scores and TIVAP indwelling time. The trial and follow-up periods each lasted approximately 12 months. <bold>Conclusion</bold> : TIVAP is a common route of access for chemotherapy in cancer patients. Ultrasound-guided implantation via BCV offers clinicians an alternative approach. This trial provides a theoretical foundation for the widespread clinical application of ultrasound-guided TIVAP implantation via BCV, with a robust experimental design ensuring the generalisability of the results. <bold>Trail Registration:</bold> The trial protocol was registered with the Chinese Clinical Trial Registry (ChiCTR2500113356). </p>